Dexcel Technologies Patent-Cliff Exposure & CMS Drug Spending Portfolio

Dexcel Technologies (US): 4 reconciled FDA prescription therapies (69.8% 2025 to 2030 cliff risk), $663.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure69.8%
Primary Portfolio LOE Date2030-01-01
2024 CMS Total Public Spend$663.0M
2024 Medicare Part D Spend$538.4M
2024 Medicaid Spend$124.6M
California HCAI SB 17 Filings2 WAC filings (max 773.6% 2-yr change)